223786-45-6

Basic information

• Product Name: 4-(4-amino-phenyl)-2,2-dimethyl-piperazine-1-carboxylic acid tert-butyl ester
• Synonyms: 4-(4-amino-phenyl)-2,2-dimethyl-piperazine-1-carboxylic acid tert-butyl ester
• CAS NO: 223786-45-6
• Molecular Weight: 305.42
• Mol File: 223786-45-6.mol
• Article Data: 5

Chemical Properties

• CAS DataBase Reference: 4-(4-amino-phenyl)-2,2-dimethyl-piperazine-1-carboxylic acid tert-butyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: 4-(4-amino-phenyl)-2,2-dimethyl-piperazine-1-carboxylic acid tert-butyl ester(223786-45-6)
• EPA Substance Registry System: 4-(4-amino-phenyl)-2,2-dimethyl-piperazine-1-carboxylic acid tert-butyl ester(223786-45-6)

Safety Data

• Hazardous Substances Data: 223786-45-6(Hazardous Substances Data)

Upstream product

• 84477-72-5 2,2-dimethylpiperazine 
• 22476-74-0 3,3-dimethyl-piperazin-2-one 
• 123-00-2 4-(3-Aminopropyl)morpholine 
• 352329-03-4 N₂-(4-Fluoro-phenyl)-pyrido[2,3-d]pyrimidine-2,7-diamine 
• 674792-07-5 2,2-dimethyl-piperazine-1-carboxylic acid tert-butyl ester 
• 350-46-9 4-Fluoronitrobenzene 
• 223786-44-5 tert-butyl 2,2-dimethyl-4-(4-nitrophenyl)piperazine-1-carboxylate 

Downstream Products

• 850628-95-4 4-[4-(8-cyclopentyl-5-methyl-7-oxo-7,8-dihydropyrido[2,3-d]pyrimidin-2-ylamino)phenyl]-2,2-dimethylpiperazine-1-carboxylic acid tert-butyl ester 
• 352329-05-6 4-[4-(7-Amino-6-fluoro-pyrido[2,3-d]pyrimidin-2-ylamino)-phenyl]-2,2-dimethyl-piperazine-1-carboxylic acid tert-butyl ester 
• 352328-33-7 1-Cyclohexyl-3-{2-[4-(3,3-dimethyl-piperazin-1-yl)-phenylamino]-pyrido[2,3-d]pyrimidin-7-yl}-urea 

Relevant articles and documents

PYRIMIDOPYRIMIDINONES USEFUL AS WEE-1 KINASE INHIBITORS

The present invention relates to compounds that are useful as inhibitors of the activity of Wee-1 kinase. The present invention also relates to pharmaceutical compositions comprising these compounds and to methods of using these compounds in the treatment of cancer and methods of treating cancer.

Pyrido[2,3-d]pyrimidin-7-ones as specific inhibitors of cyclin-dependent kinase 4

Inhibition of the cell cycle kinase, cyclin-dependent kinase-4 (Cdk4), is expected to provide an effective method for the treatment of proliferative diseases such as cancer. The pyrido[2,3-d]-pyrimidin-7-one template has been identified previously as a privileged structure for the inhibition of ATP-dependent kinases, and good potency against Cdks has been reported for representative examples. Obtaining selectivity for individual Cdk enzymes, particularly Cdk4, has been challenging. Here, we report that the introduction of a methyl substituent at the C-5 position of the pyrido[2,3-d]pvrimidin-7-one template is sufficient to confer excellent selectivity for Cdk4 vs other Cdks and representative tyrosine kinases. Further optimization led to the identification of highly potent and selective inhibitors of Cdk4 that exhibit potent antiproliferative activity against human tumor cells in vitro. The most selective Cdk4 inhibitors were evaluated for antitumor activity against MDA-MB-435 human breast carcinoma xenografts in mice.

4-Aminothiazole derivatives, their preparation and their use as inhibitors of cyclin-dependent kinases

This invention is directed to aminothiazole compounds of formula (I) wherein R1 is a substituted or unsubstituted group selected from : C1-6-alkyl; C1-6-alkenyl; C1-6-alkynyl; C1-6-alkoxyl; C1-6-alcohol; carbocyclic or heterocyclic, monocyclic or fused or non-fused polycyclic, cycloalkyl; carbocyclic or heterocyclic, monocyclic or fused or non-fused polycyclic, aryl; carbonyl; ether; (C1-6-alkyl)-carbonyl; (C1-6-alkyl)-aryl; (C1-6-alkyl)-cycloalkyl; (C1-6-alkyl)-(C1-6-alkoxyl); aryl-(C1-6-alkoxyl); thioether; thiol; and sulfonyl; wherein when R1 is substituted, each substituent independently is a halogen; haloalkyl; C1-6-alkyl; C1-6-alkenyl; C1-6-alkynyl; hydroxyl; C1-6-alkoxyl; amino; nitro; thiol, thioether; imine; cyano; amido; phosphonato; phosphine; carboxyl; thiocarbonyl; sulfonyl; sulfonamide; ketone; aldehyde; ester; oxygen; carbocyclic or heterocyclic, monocyclic or fused or non-fused polycyclic, cycloalkyl; or carbocyclic or heterocyclic, monocyclic or fused or non-fused polycyclic, aryl; and R2 is a carbocyclic or heterocyclic, monocyclic or fused or non-fused polycyclic, ring structure having a substituent at the position adjacent to the point of attachment, which ring structure is optionally further substituted, where each substituent of R2 independently is a halogen; haloalkyl; C1-6-alkyl; C1-6-alkenyl; C1-6-alkynyl; hydroxyl; C1-6-alkoxyl; amino; nitro; thiol; thioether; imine; cyano; amido; phosphonato; phosphine; carboxyl; thiocarbonyl; sulfonyl; sulfonamide; ketone; aldehyde; ester; oxygen; carbocyclic or heterocyclic, monocyclic or fused or non-fused polycyclic, cycloalkyl; or carbocyclic or heterocyclic, monocyclic or fused or non-fused polycyclic, aryl; or a pharmaceutically acceptable salt of a compound of formula (I), or a prodrug or pharmaceutically active metabolite of a compound of formula (I) or pharmaceutically acceptable salt thereof, for inhibiting cyclin-dependent kinases (CDKs), such as CDK1, CDK2, CDK4, and CDK6. The invention is also directed to the therapeutic or prophylactic use of pharmaceutical compositions containing such compounds and to methods of treating malignancies and other disorders by administering effective amounts of such compounds.